Clinical Trial

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2024 (before its estimated April 11, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-09.
Status change: Not Yet Recruiting → Recruiting 2024-04-15
Trial Details
NCT Number NCT06363825
Lead Sponsor Fujian Medical University
Conditions Advanced Hepatocellular Carcinoma
Enrollment 57 participants
Start Date 2024-04-12
Primary Completion 2026-04-11 (estimated)
Study Completion 2027-05-11 (estimated)
Updated on ClinicalTrials.gov 2024-04-17